Flash FinanceUS
Pre-market S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Penumbra (PEN)

Penumbra Q1 revenue rises 15.6% to $374.8 million; net income falls to $32.6 million

Mixed Impact 3 of 5 earnings Written later

Penumbra reported first quarter 2026 revenue of $374.8 million, up 15.6% from a year earlier, but net income fell to $32.6 million from $39.2 million and diluted earnings per share fell to $0.82 from $1.00. The company will not provide full-year 2026 guidance or hold an earnings call because of its pending acquisition by Boston Scientific.

Key points

  • Revenue of $374.8 million, up 15.6%; thrombectomy up 12.1% to $253.9 million and embolization and access up 23.8% to $120.8 million
  • Net income of $32.6 million versus $39.2 million in Q1 2025; diluted EPS of $0.82 versus $1.00
  • $9.4 million of acquisition-related expenses included in SG&A, tied to the pending Boston Scientific acquisition
  • No full-year 2026 financial guidance and no conference call, due to the pending Boston Scientific acquisition

The filing

CompanyPenumbra (PEN)
Form8-K, current report
Filed with the SECMay 6, 2026, 4:14 PM ET
Accession number0001321732-26-000018

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:12 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.